Get in touch

High-Potency Drug Manufacturing: Why Containment Strategy Matters in Oncology Production

Introduction

Modern oncology therapies are becoming increasingly specialized, and so are the manufacturing environments required to produce them. For pharmaceutical companies developing potent or cytotoxic products, conventional manufacturing controls may not be enough. The facility, equipment, processes and people must operate within a carefully designed containment strategy.

That makes high-potency pharmaceutical manufacturing fundamentally different from standard pharmaceutical production.

The challenge is twofold. Manufacturers need to protect the quality and integrity of the drug product while also controlling potential occupational exposure and cross-contamination risks associated with potent compounds.

These considerations become particularly important in oncology drug manufacturing, where active pharmaceutical ingredients and finished products may require specialized handling throughout development, scale-up and commercial production.

Selecting the right manufacturing partner therefore requires more than checking available capacity. Pharmaceutical companies need to understand how a potential CDMO approaches containment, process design, cleaning, material movement, equipment, operator practices, quality systems and commercial scale-up.

For companies evaluating an oncology CDMO company, a well-developed containment strategy can be one of the clearest indicators of whether the organization truly understands high-potency manufacturing.

What Is High-Potency Pharmaceutical Manufacturing?

High-potency pharmaceutical manufacturing involves the development and production of pharmaceutical products containing compounds that require enhanced controls because relatively small amounts may produce significant biological effects.

The exact controls required depend on the characteristics of the compound, the process and the associated risk assessment.

High-potency manufacturing can affect almost every part of pharmaceutical operations, including:

This is why high-potency manufacturing should not be viewed as a single piece of equipment or an isolated containment room.

It is a complete manufacturing strategy.

Why Is High-Potency Manufacturing Important in Oncology?

Oncology is one of the pharmaceutical areas where potent and cytotoxic compounds are particularly relevant.

Cancer therapies are designed to produce significant biological effects, and some compounds can create occupational exposure concerns if they are not handled under appropriate conditions.

This makes specialized oncology drug manufacturing capabilities important.

A manufacturing environment supporting oncology products may need to manage several priorities simultaneously:

Product quality + operator protection + environmental control + cross-contamination prevention.

These requirements can influence how materials enter the facility, how manufacturing operations are performed, how equipment is cleaned and how waste leaves controlled areas.

As a result, companies seeking oncology pharmaceutical manufacturers should evaluate actual containment expertise rather than relying only on general pharmaceutical manufacturing experience.

Containment Begins with Risk Assessment

Effective containment starts before commercial manufacturing begins.

The manufacturer needs to understand the characteristics of the compound and the risks associated with the proposed manufacturing process.

A risk-based approach helps determine the controls required for different operations.

For example, the potential exposure risk during a closed processing step may differ considerably from the risk during material charging, sampling, equipment cleaning or maintenance.

This means containment cannot simply be applied uniformly across every manufacturing stage.

The strategy should reflect where exposure can realistically occur.

A capable high-potency drug manufacturing partner should therefore evaluate the entire process and identify where engineering controls, procedural controls or additional protective measures are needed.

Why Facility Design Matters

Facility design plays a major role in high-containment manufacturing.

The physical layout should support controlled movement of people and materials while reducing opportunities for contamination to move between manufacturing areas.

Depending on the product and process, facility considerations may include:

These systems should work together.

A high-potency manufacturing facility is not effective simply because one room is isolated. The entire movement of the compound through the manufacturing process needs to be considered.

Engineering Controls Should Be the Foundation

Personal protective equipment is important, but it should not be the only line of defence in high-containment pharmaceutical manufacturing.

Engineering controls are designed to contain the process itself.

Depending on the operation, this may involve closed processing systems, barrier technologies, contained transfer systems or other equipment designed to minimize the release of pharmaceutical material.

The principle is straightforward:

Contain the compound as close to the process as possible.

This can reduce reliance on procedural controls alone and provide a more robust manufacturing environment.

When evaluating a CDMO, pharmaceutical companies should therefore ask how containment has been engineered into the manufacturing process rather than focusing only on what protective clothing operators wear.

Material Movement Is a Critical Part of Containment

Every time a potent compound moves through a facility, another potential exposure point is created.

Raw materials may need to move from receipt into dispensing and then into manufacturing. Intermediate materials may move between process steps. Finished products, samples and waste must also leave controlled manufacturing areas.

Each movement should be considered within the overall containment strategy.

An experienced oncology CDMO company should have defined systems governing:

The objective is to maintain control throughout the complete manufacturing lifecycle rather than concentrating containment only around the main production equipment.

Cleaning Is More Than a Routine Manufacturing Activity

Cleaning becomes particularly important when manufacturing potent pharmaceutical compounds.

Residues remaining on equipment or surfaces can create cross-contamination or exposure risks if they are not appropriately controlled.

Cleaning strategies therefore need to be developed according to the equipment, compound and manufacturing process.

Important considerations can include:

A robust cleaning program provides confidence that manufacturing equipment can be returned to an appropriate condition following production.

For pharmaceutical companies outsourcing cytotoxic drug manufacturing, understanding how a prospective partner manages cleaning and decontamination should be part of technical due diligence.

Cross-Contamination Control Protects More Than One Product

Cross-contamination is an important pharmaceutical quality concern, particularly when potent compounds are involved.

Even small quantities of an unintended pharmaceutical substance can create significant quality implications.

Controls should therefore be designed to prevent material from moving unintentionally between products, equipment or manufacturing areas.

Potential strategies depend on the facility and product but can involve segregation, containment, validated cleaning, controlled workflows and appropriate manufacturing scheduling.

A specialized high-potency manufacturer should be able to explain how its contamination-control strategy is connected across facility, equipment, personnel and process systems.

High-Potency Oral Solid Manufacturing Has Its Own Challenges

Not all high-potency oncology products are injectables.

Oral solid dosage forms such as tablets and capsules can also contain potent APIs.

During manufacturing, operations such as dispensing, granulation, blending, compression or encapsulation can create opportunities for pharmaceutical powders to become airborne or spread between process areas.

This makes containment important throughout the oral solid manufacturing process.

For pharmaceutical companies developing potent oral oncology products, a manufacturing partner should demonstrate experience in managing both product quality and containment during these operations.

This broadens the role of high-potency pharmaceutical manufacturing beyond sterile products alone.

Sterile High-Potency Manufacturing Adds Another Layer of Complexity

Sterile oncology products create a particularly demanding manufacturing environment.

The manufacturer must simultaneously maintain:

aseptic control to protect the sterile product
and
containment control to manage the potent compound.

These two requirements need to function together.

A sterile process cannot compromise containment, and containment systems cannot compromise the conditions required for sterile manufacturing.

For companies evaluating sterile oncology manufacturing in India, this combination should be a major part of CDMO selection.

The manufacturing partner should understand sterile processing, contamination control and potent-compound containment as interconnected requirements rather than separate technical disciplines.

Oncology Injectables Require Specialized Manufacturing Expertise

Injectable oncology products may involve liquid formulations, lyophilized products or other specialized presentations.

Manufacturing these products requires appropriate sterile processing capabilities along with expertise relevant to oncology compounds.

An experienced oncology injectables manufacturer should understand:

This combination of capabilities can be difficult to reproduce through a fragmented network of unrelated vendors.

For that reason, pharmaceutical companies increasingly evaluate specialized CDMOs capable of supporting several stages within one development and manufacturing pathway.

Why Operator Protection Matters

People remain an important consideration in pharmaceutical manufacturing.

Operators may interact with equipment, raw materials and manufacturing environments during routine production, sampling, cleaning, maintenance or other activities.

A strong containment program therefore considers how work is actually performed.

This includes appropriate training, operating procedures, engineering controls and personal protective measures based on the specific manufacturing risk.

Effective training is particularly important because even sophisticated equipment depends on correct operation.

A CDMO specializing in high-potency drug manufacturing should therefore demonstrate not only infrastructure but also the operational discipline required to use that infrastructure consistently.

Containment Should Continue During Equipment Maintenance

One area sometimes overlooked during CDMO evaluation is maintenance.

Equipment may be well contained during normal operation, but maintenance activities can introduce different exposure conditions.

Opening equipment, replacing components or troubleshooting process systems may disturb residues that are normally contained during production.

A complete containment strategy should therefore consider non-routine operations as well as normal manufacturing.

The same applies to cleaning, equipment changeover and waste handling.

This is another reason containment needs to be viewed as an operational system rather than simply a production-room feature.

Technology Transfer for High-Potency Products

Moving a potent product from development to commercial manufacturing requires careful technology transfer.

The receiving manufacturing team needs to understand both the pharmaceutical process and the containment requirements associated with that process.

Important transfer information can include:

Early communication between development, engineering, manufacturing and quality teams can help identify potential challenges before commercial production begins.

A CDMO capable of supporting both development and manufacturing can provide greater continuity during this transition.

Scale-Up Can Change Containment Requirements

A process that is manageable at laboratory scale may behave differently at commercial scale.

Larger material quantities, different equipment and increased process duration can change how potential exposure risks need to be managed.

For example, material-transfer operations may differ substantially between small development batches and full commercial batches.

This means containment should be reassessed as the manufacturing process scales.

A capable oncology CDMO company should consider commercial containment requirements during development rather than waiting until the process is ready for launch.

This approach can reduce the likelihood of discovering major facility or process limitations late in development.

Quality Systems Are Essential to High-Potency Manufacturing

Containment is not only an engineering responsibility.

Quality systems provide the framework that keeps manufacturing operations controlled and documented.

Relevant systems may include:

For pharmaceutical companies considering pharmaceutical contract manufacturing in India, evaluating these systems helps determine whether the CDMO can consistently support the required manufacturing standards.

A technically advanced facility needs equally strong quality processes behind it.

How to Evaluate a High-Potency Manufacturing Partner

Before selecting a manufacturing partner, pharmaceutical companies should evaluate several areas together.

Relevant Product Experience

Does the CDMO have experience handling oncology, cytotoxic or other potent pharmaceutical products?

Containment Strategy

Can the company clearly explain how containment is designed around the manufacturing process?

Facility and Equipment

Does the infrastructure support the intended dosage form and containment requirements?

Sterile Manufacturing

If the product is injectable, can the partner combine aseptic manufacturing with high-potency controls?

Development Capability

Can formulation, analytical development and process development be supported before commercial production?

Technology Transfer

Is there a structured process for moving product and process knowledge into manufacturing?

Commercial Scale

Can the containment strategy operate effectively at the required production scale?

Quality Systems

Are manufacturing and containment supported by appropriate documentation, validation and quality oversight?

Looking at these areas together provides a much more realistic assessment than comparing manufacturing capacity alone.

Why Specialized Oncology CDMOs Can Add Value

General pharmaceutical manufacturing experience is valuable, but oncology products can demand more specialized capabilities.

A focused oncology CDMO can bring together expertise across:

R&D → High-Potency Handling → Sterile/Non-Sterile Manufacturing → Technology Transfer → Scale-Up → Commercial Production

This integrated model can help reduce technical handoffs and preserve product knowledge as a program advances.

It can also make it easier to address containment considerations early, when formulation and process decisions can still be optimized.

For global pharmaceutical companies, the right partner should therefore be evaluated as part of the product’s long-term commercialization strategy rather than merely as a manufacturing vendor.

Teyro’s Focus on Oncology and High-Potency Manufacturing

Teyro’s pharmaceutical development and manufacturing capabilities are built around specialized areas including oncology, high-potency products, sterile manufacturing and non-sterile dosage forms.

The company’s capabilities span pharmaceutical R&D, analytical and stability activities, technology transfer, scale-up and commercial manufacturing.

This integrated approach is particularly relevant for oncology products where development decisions, containment requirements and commercial manufacturing need to remain connected.

Teyro’s manufacturing capabilities support sterile and non-sterile products, including oncology injectables and oral solid dosage forms.

For pharmaceutical companies seeking an oncology CDMO company or specialized high-potency pharmaceutical manufacturing partner in India, this creates a pathway for supporting products from development through commercial production.

High-Potency Manufacturing Partner Checklist

Before selecting a CDMO, consider asking:

These questions can reveal whether containment is genuinely embedded into the organization’s manufacturing strategy.

Conclusion

Successful high-potency pharmaceutical manufacturing depends on far more than isolating a potent compound inside a production room.

Containment needs to extend across facility design, equipment, material movement, personnel practices, cleaning, maintenance, waste handling, quality systems, technology transfer and commercial scale-up.

For oncology products, the challenge can become even more complex when potent-compound handling must be combined with sterile injectable or specialized oral solid manufacturing.

This is why pharmaceutical companies should carefully evaluate the technical depth of potential manufacturing partners.

The right oncology CDMO company should understand the product, the process and the containment requirements as one connected manufacturing system.

When containment considerations are addressed early—from development through commercial production—pharmaceutical companies can build a more controlled, scalable and reliable manufacturing pathway for complex oncology therapies.